Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 99 P92 | DOI: 10.1530/endoabs.99.P92

ECE2024 Poster Presentations Endocrine-Related Cancer (40 abstracts)

How well does ‘real world’ management of Immune check point inhibitor induced hypophysits (ICI-Hp) reflect the European Society of Endocrinology (ESE) 2023 clinical practice guidelines (CPG)?: Experience from a single tertiary care centre

Shani Apsara Dilrukshi Mathara Diddhenipothage 1 , Jacqui Warden 2 , Katie Herbert 2 , Riccardo Pofi 1 , Nicholas Coupe 2 , Miranda Payne 2 , Jeremy W Tomlinson 1 & Helen Turner 1


1Oxford Centre for Diabetes, Endocrinology, and Metabolism, Endocrinology, Oxford, UK; 2Department of Oncology, Churchill Hospital, Oxford, UK


Introduction: Hypophysitis (Hp) is a serious adverse effect (AE) of Immune check-point inhibitor (ICI) therapy in malignancy. We evaluated 6 yeas of clinical expereince with ICI against the recent ESE CPG 2023 which provides practical guidance on the management of this condition based on up-to-date evidence.

Methods: A quality improvement project (QIP) included all patients with ICI-Hp (n=17) referred to a dedicated Endocrine-ICI clinic (January 2017-November 2023), to determine presentation, management, and outcomes.

Results: There were 50% males, median age 63 y (IQR 51,73)] and symptom onset occurred 12 w (IQR 9,15) of ICI therapy, after the 3rd (IQR 3,4) cycle; underlying malignancy: metastatic melanoma (76%), renal cell carcinoma (12%) and mesothelioma (12%). All received Ipilimumab (Ipi), alone (5.8%) or in combination with Nivolumab (82%). Fatigue (76%), headache (71%) and nausea (65%) were common symptoms; 12% were asymptomatic. Hyponatremia 41%. All had acute secondary hypocortisolism (SHC) (random morning cortisol <100 nmol/l in 82%, <50 nmol/l in 53%). Acute secondary hypothyroidism (SHT) and hypogonadism (SHG) were reported in 35%. Low prolactin (PRL) (<110 mIU/l) 30%; elevated PRL (446-1119) 18%. Enlarged pituitary was the commonest (75%) pituitary imaging abnormality (n=16, performed ≤12 w), followed by thickened stalk (31%), supra-sellar extension (12%), mild optic-chiasm compression (n=1, biopsy: lymphocytic Hp). Specific management of Hp varied; IV methylprednisolone (MPP) 1 mg/kg per day (n=4) (indication severe headache), oral prednisolone 30–40 mg/d (n=6), oral dexamethasone 10 mg/d (n=1), and hydrocortisone (HC) 40 mg/d for 48 h (n=4). Symptomatic Hp recovery occurred in all; (33% within 48 h) and scan abnormalities [at 15 w (IQR 13, 22), n=14). One patient developed acute psychosis with high-dose MPP. Long term, all received standard HC (20 mg/d) replacement and age/weight-based levothyroxine in persistent SHT. None required sex hormone replacement. In those evaluated for pituitary recovery; There was no recovery in SHC (n=10), whilst recovery of SHT and SHG was reported in 43% [at 5 w (IQR 4,10)] and 67% [at 10 w (IQR 8,13)] respectively. Lack of cancer progression was noted in 65% [2.5 y (IQR 2, 6)]. Treatment with high dose GCs was not associated with cancer progression (P=1.00), or all-cause mortality (P=0.515).

Conclusions: Despite antedating ESE CPG, our practice is aligned with current guidance. GC dose (not strictly aligned with CPG) chosen for symptom severity had no effect on disease course. SHC following ICI-HP was irreversible, however recovery of SHT and SHG should be actively sought on long term follow up.

Volume 99

26th European Congress of Endocrinology

Stockholm, Sweden
11 May 2024 - 14 May 2024

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.